Review Article: An Update on Non‐Invasive Tests for Steatotic Liver Disease ‐ Insights From the ESSENCE Phase 3 Trial and Longitudinal Studies

Key Points

• The aim is to update knowledge on non-invasive tests for diagnosing and managing steatotic liver disease.
• Analyzed findings from the ESSENCE Phase 3 Trial
• Reviewed longitudinal studies on at-risk MASH
• Evaluated pharmacologic treatments including semaglutide
• Treatment with semaglutide is recommended for patients with high-risk MASH
• Highlights improved outcomes in patients showing severity of liver conditions
• Suggests a need for ongoing evaluation of non-invasive testing methods